Investigational drug · Phase 3
BEBT-209
Also called: KCBI-0191
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HR+/HER2- Locally Advanced, Metastatic Breast Cancer, Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "BEBT-209"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BEBT-209", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR+/HER2- Locally Advanced, Metastatic Breast Cancer
- Locally Advanced Triple-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple-Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BEBT-209" as an intervention, largest first.
- A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerPivotal-lookingRecruiting
BeBetter Med IncIndustry
NCT07544056 · 446 participants (planned) · Start Jun 4, 2026 · Primary completion Jun 2030
Drug: BEBT-209 capsules; Carboplatin Injection and 1 more · For: Locally Advanced Triple-negative Breast Cancer; Metastatic Triple-negative Breast Cancer
Sites: Guangzhou, China; Changsha, China
- Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyPivotal-lookingRecruiting
BeBetter Med IncIndustry
NCT06998108 · 330 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 31, 2025
Drug: BEBT-209 capsules; BEBT-209 Placebo capluses and 1 more · For: HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Sites: Beijing, China
BeBetter Med IncIndustry
NCT06047184 · 100 participants · Start Jul 15, 2019 · Primary completion Jan 30, 2024
Drug: BEBT-209 capsules; Letrozole tablets and 1 more · For: Advanced Breast Cancer
Sites: Changsha, China · 2 sites in all
BeBetter Med IncIndustry
NCT06685796 · 65 participants · Start Apr 12, 2023 · Primary completion Apr 20, 2026
Drug: BEBT-209 capsules; Carboplatin injection and 1 more · For: Advanced Triple-Negative Breast Cancer
Sites: Guangzhou, China; Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.
Hu ZY, Jiang K, Tian C, et al. · Breast 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.